FindTrial
Sign In

Construction and validation of a model for predicting malignant phenotype, treatment response, and prognosis of upper tract urothelial carcinoma based on radiomics

Clinical research on predicting the clinicopathological characteristics and prognosis of upper urinary tract urothelial carcinoma based on enhanced CT imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118974
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-02-13
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper urinary tract urothelial carcinoma

Interventions

Gold Standard:Postoperative pathology confirmed urothelial carcinoma
Index test:Imaging-omics prediction model based on enhanced CT

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Complete CT and MRI examinations at our hospital within 3 months before surgery (2) From 2017 to 2023, patients underwent surgical treatment at our hospital, and postoperative pathology confirmed them to have upper tract urothelial carcinoma (UTUC)

Exclusion criteria

Exclusion criteria: (1) Unilateral kidney, solitary kidney, patient with previous kidney surgery (2) Preoperative renal function status does not meet the criteria for neoadjuvant chemotherapy (3) Patients with bilateral upper tract urothelial carcinoma (UTUC) (4) Pregnant women (5) Patients that other researchers believe should be excluded.

Design outcomes

Primary

MeasureTime frame
Area Under the Receiver Operating Characteristic Curve, AUC;—

Secondary

MeasureTime frame
Sensitivity;Specificity;—

Countries

China

Contacts

Public ContactLi Xuesong

Peking University First Hospital

pineneedle@sina.com+86 158 0139 9116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026